P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS

Bibliographic Details
Main Authors:	Kristine Frerichs, Christie Verkleij, Maria-Victoria Mateos, Sonja Zweegman, Kaz Groen, Ilse Kuipers, Tom Martin, Cesar Rodriguez, Ajay Nooka, Sandy Kruijswijk, Sheri Skerget, Margaret Doyle, Arnob Banerjee, Katherine Chastain, Alfredo Perales-Puchalt, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Raluca Verona, Niels W.C.J. van de Donk
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972904.51933.45

Similar Items

Teclistamab: Mechanism of action, clinical, and translational science
by: Yue Guo, et al.
Published: (2024-01-01)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
by: Niels W.C.J. van de Donk, et al.
Published: (2023-08-01)

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
by: NWCJV Donk, et al.
Published: (2023-10-01)

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS
by: C. Touzeau, et al.
Published: (2022-06-01)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Surbhi Sidana, et al.
Published: (2023-08-01)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
by: Kristine A. Frerichs, et al.
Published: (2019-12-01)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: A. Krishnan, et al.
Published: (2022-06-01)

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
by: J. Martínez-López, et al.
Published: (2022-06-01)

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: M. V. Mateos, et al.
Published: (2022-06-01)

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
by: Amrita Krishnan, et al.
Published: (2023-04-01)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: N. van de Donk, et al.
Published: (2023-05-01)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: R Popat, et al.
Published: (2022-04-01)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
by: L. Rosinol, et al.
Published: (2022-06-01)

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON
by: M. Delforge, et al.
Published: (2022-06-01)

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
by: Sara A. Scott, et al.
Published: (2023-12-01)

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS
by: Wassilis Bruins, et al.
Published: (2023-08-01)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
by: Manisha Bhutani, et al.
Published: (2023-08-01)

Varia: Centenarios, 1506-2006
by: Diego Suárez Quevedo
Published: (2006-01-01)

P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Philippe Moreau, et al.
Published: (2023-08-01)

Chronologie du Yémen (1506-1635)
by: Michel Tuchscherer
Published: (2000-06-01)

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
by: Rajshekhar Chakraborty, et al.
Published: (2023-11-01)

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY
by: H. Einsele, et al.
Published: (2022-06-01)

Impressive extramedullary plasmacytoma response in refractory multiple myeloma treated with teclistamab
by: Intissar Ben Salah, et al.
Published: (2024-02-01)

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
by: Fritz Offner, et al.
Published: (2023-08-01)

Emigrantes a la isla Española en 1506
by: Juan Gil
Published: (2006-12-01)

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
by: Meera Mohan, et al.
Published: (2024-03-01)

First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
by: Nelson Leung, et al.
Published: (2023-11-01)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
by: Mashhour Hosny, et al.
Published: (2021-10-01)

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
by: P Rodriguez-Otero, et al.
Published: (2022-04-01)

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
by: Carlyn Tan, et al.
Published: (2023-08-01)

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01)

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
by: R. Popat, et al.
Published: (2022-06-01)

689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2
by: Lien Vandenberk, et al.
Published: (2023-11-01)

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody
by: Pan D, et al.
Published: (2023-07-01)

Relations between the Grand Duchy of Lithuania and Kazan Khanate (1506–1552)
by: Ya.V. Pilipchuk
Published: (2014-09-01)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
by: Christie P. M. Verkleij, et al.
Published: (2020-12-01)

Il libro segreto dell’Archivio della curia romana (1506-1524)
by: Corinna Drago Tedeschini
Published: (2019-12-01)

S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS
by: P. Rodriguez Otero, et al.
Published: (2022-06-01)

Immunotherapy in myeloma: Why, when and how?
by: Niels W.C.J. van de Donk
Published: (2018-06-01)

Zachowany rękopis patrologiczny z księgozbioru biskupa Jana IV Rotha (1482-1506)
by: Wincenty Urban
Published: (1980-03-01)